FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897985584> ?p ?o ?g. }

• W2897985584 endingPage "421" @default.
• W2897985584 startingPage "408" @default.
• W2897985584 abstract "This work evaluates several compositions of an amorphous solid dispersion (ASD) comprising nimodipine (NMD) as poorly soluble model API in a dual-polymer carrier system. HPMC E5 and Eudragit E were used for the two polymeric carriers. The formulation was designed for hot-melt extrusion (HME) and subsequent strand pelletization. The aim was to identify a formulation window with desired functional ASD performance, i.e. physical stability and immediate API release, as well as processability in strand pelletization. Samples were prepared using small-scale methods, such as vacuum compression molding (VCM) and benchtop extrusion. Miscibility and phase studies were performed for a wide range of polymer ratios and three levels of API content (10–30% w/w). Ternary ASD formulations were phase-separated, yet physically stable upon exposure to elevated temperature/humidity. A study of phase composition showed that the drug molecules were predominantly solubilized in the Eudragit E fraction of the formulation. The miscibility study and Fourier-transform infrared spectroscopy indicated hydrogen (H)bond interactions between NMD and Eudragit E. In HPMC, the amorphous API was dispersed in polymeric matrix and stabilized due to anti-plasticization and the disruption of intermolecular Hbonding between API molecules. Concerning processability in strand pelletization the formulation is limited at high Eudragit E content. NMD and EE-rich phases exhibit low mixture glass transition, low melt stability and brittle breaking behavior upon strand cutting. The high viscosity and yield point of HPMC contributes to the mechanical robustness of the strand at temperatures relevant for processing. Formulation-intrinsic dissolution rates in VCM ASDs developed as an irregular function of polymer ratio, associated with diverse and competitive dissolution mechanisms in the polymers. With regard to the binary system of NMD with HPMC E5, surface crystallization was observed in VCM ASDs. For extruded pellets this was not the case, and a steady trend of formulation-intrinsic dissolution rate across different polymer ratios was observed. These discrepancies indicated a major influence of shear stress during sample preparation on HPMC-based ASD performance. Finally, a feasible formulation window within a polymer ratio of 1:2–2:3 Eudragit E:HPMC was identified in which Eudragit E acts as a dissolution rate enhancer and ASD stabilizer during dissolution." @default.
• W2897985584 created "2018-10-26" @default.
• W2897985584 creator A5023848615 @default.
• W2897985584 creator A5033515798 @default.
• W2897985584 creator A5035675480 @default.
• W2897985584 creator A5040003588 @default.
• W2897985584 creator A5046568778 @default.
• W2897985584 creator A5062413476 @default.
• W2897985584 date "2018-12-01" @default.
• W2897985584 modified "2023-10-17" @default.
• W2897985584 title "Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization" @default.
• W2897985584 cites W1595400931 @default.
• W2897985584 cites W1692784501 @default.
• W2897985584 cites W1711565551 @default.
• W2897985584 cites W1834368260 @default.
• W2897985584 cites W1975030247 @default.
• W2897985584 cites W1977160619 @default.
• W2897985584 cites W1985032283 @default.
• W2897985584 cites W1995253850 @default.
• W2897985584 cites W1999002078 @default.
• W2897985584 cites W2006496622 @default.
• W2897985584 cites W2014879978 @default.
• W2897985584 cites W2020942290 @default.
• W2897985584 cites W2022006632 @default.
• W2897985584 cites W2024086383 @default.
• W2897985584 cites W2036213853 @default.
• W2897985584 cites W2039290656 @default.
• W2897985584 cites W2041756464 @default.
• W2897985584 cites W2044146593 @default.
• W2897985584 cites W2047948690 @default.
• W2897985584 cites W2049887523 @default.
• W2897985584 cites W2051055753 @default.
• W2897985584 cites W205849754 @default.
• W2897985584 cites W2060159183 @default.
• W2897985584 cites W2067297412 @default.
• W2897985584 cites W2069580393 @default.
• W2897985584 cites W2073352795 @default.
• W2897985584 cites W2076633179 @default.
• W2897985584 cites W2077578726 @default.
• W2897985584 cites W2079193883 @default.
• W2897985584 cites W2085535677 @default.
• W2897985584 cites W2092618151 @default.
• W2897985584 cites W2093248776 @default.
• W2897985584 cites W2133061394 @default.
• W2897985584 cites W2149111315 @default.
• W2897985584 cites W2153813502 @default.
• W2897985584 cites W2155510850 @default.
• W2897985584 cites W2254923502 @default.
• W2897985584 cites W2316305032 @default.
• W2897985584 cites W2317854092 @default.
• W2897985584 cites W2747357009 @default.
• W2897985584 cites W2885065463 @default.
• W2897985584 doi "https://doi.org/10.1016/j.ijpharm.2018.10.035" @default.
• W2897985584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30326284" @default.
• W2897985584 hasPublicationYear "2018" @default.
• W2897985584 type Work @default.
• W2897985584 sameAs 2897985584 @default.
• W2897985584 citedByCount "18" @default.
• W2897985584 countsByYear W28979855842019 @default.
• W2897985584 countsByYear W28979855842020 @default.
• W2897985584 countsByYear W28979855842021 @default.
• W2897985584 countsByYear W28979855842022 @default.
• W2897985584 countsByYear W28979855842023 @default.
• W2897985584 crossrefType "journal-article" @default.
• W2897985584 hasAuthorship W2897985584A5023848615 @default.
• W2897985584 hasAuthorship W2897985584A5033515798 @default.
• W2897985584 hasAuthorship W2897985584A5035675480 @default.
• W2897985584 hasAuthorship W2897985584A5040003588 @default.
• W2897985584 hasAuthorship W2897985584A5046568778 @default.
• W2897985584 hasAuthorship W2897985584A5062413476 @default.
• W2897985584 hasConcept C110884469 @default.
• W2897985584 hasConcept C122865956 @default.
• W2897985584 hasConcept C127413603 @default.
• W2897985584 hasConcept C159985019 @default.
• W2897985584 hasConcept C178790620 @default.
• W2897985584 hasConcept C185592680 @default.
• W2897985584 hasConcept C192562407 @default.
• W2897985584 hasConcept C2778958987 @default.
• W2897985584 hasConcept C42360764 @default.
• W2897985584 hasConcept C521977710 @default.
• W2897985584 hasConcept C56052488 @default.
• W2897985584 hasConceptScore W2897985584C110884469 @default.
• W2897985584 hasConceptScore W2897985584C122865956 @default.
• W2897985584 hasConceptScore W2897985584C127413603 @default.
• W2897985584 hasConceptScore W2897985584C159985019 @default.
• W2897985584 hasConceptScore W2897985584C178790620 @default.
• W2897985584 hasConceptScore W2897985584C185592680 @default.
• W2897985584 hasConceptScore W2897985584C192562407 @default.
• W2897985584 hasConceptScore W2897985584C2778958987 @default.
• W2897985584 hasConceptScore W2897985584C42360764 @default.
• W2897985584 hasConceptScore W2897985584C521977710 @default.
• W2897985584 hasConceptScore W2897985584C56052488 @default.
• W2897985584 hasFunder F4320326816 @default.
• W2897985584 hasIssue "1-2" @default.
• W2897985584 hasLocation W28979855841 @default.
• W2897985584 hasLocation W28979855842 @default.
• W2897985584 hasOpenAccess W2897985584 @default.
• W2897985584 hasPrimaryLocation W28979855841 @default.

• next